{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:29:28Z","timestamp":1794533368691,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Cardiovasc Health"],"DOI":"10.1038\/s44325-026-00146-1","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:05:30Z","timestamp":1783663530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss"],"prefix":"10.1038","volume":"3","author":[{"given":"Karthik","family":"Murugadoss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Venkatakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venky","family":"Soundararajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"146_CR1","doi-asserted-by":"publisher","first-page":"102848","DOI":"10.1016\/j.eclinm.2024.102848","volume":"76","author":"X-D Zhou","year":"2024","unstructured":"Zhou, X.-D. et al. Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021. EClinicalMedicine 76, 102848 (2024).","journal-title":"EClinicalMedicine"},{"key":"146_CR2","doi-asserted-by":"publisher","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2306963 (2023).","DOI":"10.1056\/NEJMoa2306963"},{"key":"146_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield, J. et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 404, 773\u2013786 (2024).","journal-title":"Lancet"},{"key":"146_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","volume":"13","author":"S Wharton","year":"2025","unstructured":"Wharton, S. et al. Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diab. Endocrinol. 13, 949\u2013963 (2025).","journal-title":"Lancet Diab. Endocrinol."},{"key":"146_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"146_CR6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire, D. K. et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N. Engl. J. Med. 392, 2001\u20132012 (2025).","journal-title":"N. Engl. J. Med."},{"key":"146_CR7","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca, M. P. et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 405, 1580\u20131593 (2025).","journal-title":"Lancet"},{"key":"146_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"146_CR9","first-page":"25340314","volume":"11","author":"AJ Venkatakrishnan","year":"2025","unstructured":"Venkatakrishnan, A. J., Murugadoss, K. & Soundararajan, V. Decoding the hallmarks of GLP-1RA weight-loss super responders. medRxiv 11, 25340314 (2025).","journal-title":"medRxiv"},{"key":"146_CR10","doi-asserted-by":"crossref","unstructured":"Venkatakrishnan, A. J., Murugadoss, K. & Soundararajan, V. Weight-loss dynamics with tirzepatide versus semaglutide. PNAS Nexus 5, pgag171 (2026).","DOI":"10.1093\/pnasnexus\/pgag171"},{"key":"146_CR11","doi-asserted-by":"crossref","unstructured":"Murugadoss, K., Varma, G., Venkatakrishnan, A. J., Gibson, C. M. & Soundararajan, V. Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network. Biol. Methods Protoc. 11, bpag020 (2026).","DOI":"10.1093\/biomethods\/bpag020"},{"key":"146_CR12","doi-asserted-by":"publisher","unstructured":"Venkatakrishnan, A. J. et al. Clinical nSights: a software platform to accelerate real world oncology analyses. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e23316 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.e23316"},{"key":"146_CR13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"146_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41591-025-04102-x","volume":"32","author":"N Kr\u00fcger","year":"2025","unstructured":"Kr\u00fcger, N. et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Nat. Med. 32, 342\u2013352 (2025).","journal-title":"Nat. Med."},{"key":"146_CR15","doi-asserted-by":"crossref","unstructured":"Wilson, L. et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). Diabetes, Obes. Metab. 28, 2403\u20132415, (2026).","DOI":"10.1111\/dom.70436"},{"key":"146_CR16","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield, J. et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 406, 2257\u20132268 (2025).","journal-title":"Lancet"},{"key":"146_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","volume":"165","author":"Y Liu","year":"2016","unstructured":"Liu, Y., Beyer, A. & Aebersold, R. On the dependency of cellular protein levels on mRNA abundance. Cell 165, 535\u2013550 (2016).","journal-title":"Cell"},{"key":"146_CR18","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/en.2018-00004","volume":"159","author":"LL Baggio","year":"2018","unstructured":"Baggio, L. L. et al. GLP-1 receptor expression within the human heart. Endocrinology 159, 1570\u20131584 (2018).","journal-title":"Endocrinology"},{"key":"146_CR19","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1210\/en.2018-00196","volume":"159","author":"G Iacobellis","year":"2018","unstructured":"Iacobellis, G. Letter to the Editor: GLP-1 receptor expression within the human heart. Endocrinology 159, 1964\u20131965 (2018).","journal-title":"Endocrinology"},{"key":"146_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.cmet.2023.02.002","volume":"35","author":"B Maniyadath","year":"2023","unstructured":"Maniyadath, B., Zhang, Q., Gupta, R. K. & Mandrup, S. Adipose tissue at single-cell resolution. Cell Metab. 35, 386\u2013413 (2023).","journal-title":"Cell Metab."},{"key":"146_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41586-022-04518-2","volume":"603","author":"MP Emont","year":"2022","unstructured":"Emont, M. P. et al. A single-cell atlas of human and mouse white adipose tissue. Nature 603, 926\u2013933 (2022).","journal-title":"Nature"},{"key":"146_CR22","doi-asserted-by":"publisher","unstructured":"Tarhan, L. et al. Single Cell Portal: an interactive home for single-cell genomics data. Preprint at https:\/\/doi.org\/10.1101\/2023.07.13.548886 (2023).","DOI":"10.1101\/2023.07.13.548886"},{"key":"146_CR23","doi-asserted-by":"crossref","unstructured":"Siraj, M. A. et al. Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-\u03b1. J. Clin. Invest. 130,1392\u20131404 (2020).","DOI":"10.1172\/JCI99934"},{"key":"146_CR24","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jdi.13302","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu, Y., Kubota, S., Iizuka, K. & Yabe, D. Cardioprotective effects of GLP-1(28-36a): a degraded metabolite or GLP-1\u2019s better half? J. Diab. Investig. 11, 1422\u20131425 (2020).","journal-title":"J. Diab. Investig."},{"key":"146_CR25","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez, P. J. et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw. Open 8, e2457349 (2025).","journal-title":"JAMA Netw. Open"},{"key":"146_CR26","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.eclinm.2025.103680","volume":"90","author":"C-C Tzang","year":"2025","unstructured":"Tzang, C.-C. et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. EClinicalMedicine 90, 103680 (2025).","journal-title":"EClinicalMedicine"},{"key":"146_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/ehjqcco\/qcad061","volume":"10","author":"R Roy","year":"2024","unstructured":"Roy, R. et al. Diagnostic accuracy, clinical characteristics, and prognostic differences of patients with acute myocarditis according to inclusion criteria. Eur. Heart J. Qual. Care Clin. Outcomes 10, 366\u2013378 (2024).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"146_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5","volume":"21","author":"E Bosco","year":"2021","unstructured":"Bosco, E., Hsueh, L., McConeghy, K. W., Gravenstein, S. & Saade, E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med. Res. Methodol. 21, 241 (2021).","journal-title":"BMC Med. Res. Methodol."},{"key":"146_CR29","doi-asserted-by":"publisher","first-page":"e92286","DOI":"10.1371\/journal.pone.0092286","volume":"9","author":"N McCormick","year":"2014","unstructured":"McCormick, N., Lacaille, D., Bhole, V. & Avina-Zubieta, J. A. Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PLoS ONE 9, e92286 (2014).","journal-title":"PLoS ONE"},{"key":"146_CR30","doi-asserted-by":"publisher","first-page":"e104519","DOI":"10.1371\/journal.pone.0104519","volume":"9","author":"N McCormick","year":"2014","unstructured":"McCormick, N., Lacaille, D., Bhole, V. & Avina-Zubieta, J. A. Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis. PLoS ONE 9, e104519 (2014).","journal-title":"PLoS ONE"},{"key":"146_CR31","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58227","volume":"9","author":"T Wagner","year":"2020","unstructured":"Wagner, T. et al. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. Elife 9, e58227 (2020).","journal-title":"Elife"},{"key":"146_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00151","volume":"8","author":"H Barman","year":"2024","unstructured":"Barman, H. et al. Identification and characterization of immune checkpoint inhibitor-induced toxicities from electronic health records using natural language processing. JCO Clin. Cancer Inform. 8, e2300151 (2024).","journal-title":"JCO Clin. Cancer Inform."},{"key":"146_CR33","unstructured":"OpenAI et al. gpt-oss-120b & gpt-oss-20b Model Card (2025)."},{"key":"146_CR34","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gkae1142","volume":"53","author":"CZI Cell Science Program","year":"2025","unstructured":"Cell Science Program, C. Z. I. et al. CZ CELLxGENE Discover: a single-cell data platform for scalable exploration, analysis and modeling of aggregated data. Nucleic Acids Res. 53, D886\u2013D900 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["npj Cardiovascular Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44325-026-00146-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44325-026-00146-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44325-026-00146-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:02:35Z","timestamp":1783983755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44325-026-00146-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1038\/s44325-026-00146-1","relation":{},"ISSN":["2948-2836"],"issn-type":[{"value":"2948-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are employees of nference, inc., which conducts research collaborations with various biopharmaceutical companies whose therapeutic products are included in this study. None of these companies, nor any other nference collaborator, funded, supported, or had any role in the independent study design, data acquisition, analysis, interpretation, manuscript preparation, or the decision to submit this work for publication. All analyses were conducted by the authors using de-identified electronic health record data. The authors declare no additional competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}